The epidermal growth factor receptor and its ligands in cardiovascular disease.

Published online

Journal Article (Review)

The epidermal growth factor receptor (EGFR) family and its ligands serve as a switchboard for the regulation of multiple cellular processes. While it is clear that EGFR activity is essential for normal cardiac development, its function in the vasculature and its role in cardiovascular disease are only beginning to be elucidated. In the blood vessel, endothelial cells and smooth muscle cells are both a source and a target of EGF-like ligands. Activation of EGFR has been implicated in blood pressure regulation, endothelial dysfunction, neointimal hyperplasia, atherogenesis, and cardiac remodeling. Furthermore, increased circulating EGF-like ligands may mediate accelerated vascular disease associated with chronic inflammation. Although EGFR inhibitors are currently being used clinically for the treatment of cancer, additional studies are necessary to determine whether abrogation of EGFR signaling is a potential strategy for the treatment of cardiovascular disease.

Full Text

Duke Authors

Cited Authors

  • Makki, N; Thiel, KW; Miller, FJ

Published Date

  • October 15, 2013

Published In

Volume / Issue

  • 14 / 10

Start / End Page

  • 20597 - 20613

PubMed ID

  • 24132149

Pubmed Central ID

  • 24132149

Electronic International Standard Serial Number (EISSN)

  • 1422-0067

Digital Object Identifier (DOI)

  • 10.3390/ijms141020597

Language

  • eng

Conference Location

  • Switzerland